 |
|
|
| |
REBOUND DYNAMICS FOLLOWING IMMUNOTHERAPY
WITH AN HIV VACCINE, TLR-9 AGONIST, AND
BROADLY NEUTRALIZING ANTIBODIES
|
| |
| |
CROI 2023
Michael Peluso1, Amelia Deitchman1, Gesham Magombedze2, Meghann Williams1, Rebecca Hoh1, Nitasha Kumar1, Michiko Shimoda1, Mandana Khalili1, Sandeep Narpala3, Leonid Serebryannyy3 Richard Koup3, Harriet Robinson4, Marina Caskey5, Kara Chew6, Lillian Cohn7, Romas Geleziunas2, Devi SenGupta2, James Mullins8, Mary Kearney9, Barbara Felber9, George Pavlakis9, Christos Petropoulos10, Jackie Reeves10, Rowena Johnston11, Lucio Gama3, Michel Nussenzweig5, Timothy Henrich1, Rachel Rutishauser1, Steven Deeks1, for the UCSF-amfAR Study Team
1University of California, San Francisco, CA, USA, 2Gilead Sciences, Foster City, CA, USA, 3Vaccine Research Center, Bethesda, MD, USA, 4GeoVax, Atlanta, GA, USA, 5Rockefeller University, New York, NY, USA, 6University California, Los Angeles, CA, USA, 7Fred Hutch Cancer Center, Seattle, WA, USA, 8University of Washington, Seattle, WA, USA, 9National Institutes of Health, Bethesda, MD, USA, 10Monogram Biosciences, South San Francisco, CA, USA, 11amfAR, New York, NY, USA
|
| |
|
|
|
|
|
